Novartis
May 25, 2012 at 18:03 | Source: Moneycontrol.com
May 10, 2012 at 15:46 | Source: Reuters
Apr 18, 2012 at 10:35 | Source: Forbes India
Mar 14, 2012 at 12:56 | Source: Moneycontrol.com
Mar 12, 2012 at 13:30 | Source: Moneycontrol.com
Jan 31, 2012 at 18:47 | Source: Moneycontrol.com
News across the web »
May 26, 2012 at 16:12 | Source: Economic Times
May 25, 2012 at 22:26 | Source: FirstPost
May 25, 2012 at 06:42 | Source: Business Standard
May 24, 2012 at 15:20 | Source: Economic Times
May 24, 2012 at 11:56 | Source: Economic Times
Interact & exchange stock tips & market info »
Related News »
It is a good thing for long-term investors when the market only looks at things a quarter or two at a time. This short-sightedness causes lots of day-to-day volatility, but it can also create some attractive bargains. Lately, for example, the market has ...
May 24, 2012 at 16:33 | Source: Seekingalpha.com
A Novartis experimental lung drug to treat smokers' cough was superior to a placebo in improving lung function over a one-year period and had similar efficacy to a rival drug from Pfizer and Boehringer Ingelheim, the Swiss drugmaker said on ...
May 17, 2012 at 13:00 | Source: FOX News
(RTTNews) - Novartis India Ltd. Said its board recommended a dividend of 200 percent or Rs.10.00 per equity share of Rs.5 each for the fiscal year 012. dividend, if approved by the shareholders in the AGM to be held on July 25, shall be paid on or after ...
May 24, 2012 at 09:52 | Source: RTT News
Switzerland-based pharmaceutical company, Novartis AG ( NVS) recently announced positive phase III data from the GLOW 2 study of its pipeline candidate NVA237. The candidate is being studied for the treatment of chronic obstructive pulmonary ...
May 21, 2012 at 13:38 | Source: NASDAQ
Switzerland-based pharmaceutical company, Novartis AG (NVS - Snapshot Report) recently announced that positive data on Lucentis was presented at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The data presented at ...
May 15, 2012 at 15:25 | Source: Zacks.com
WASHINGTON (Reuters) - Health regulators said on Monday they could not definitively link Novartis AG's multiple sclerosis pill Gilenya with the deaths of people who took the drug. The Food and Drug Administration said the deaths included a ...
May 14, 2012 at 21:39 | Source: msnbc.com
ZURICH (Reuters) - Swiss drugmaker Novartis said on Thursday data from key studies showed treatment with its Lucentis drug could help certain sight-impaired patients see better over an extended period and that individualized treatment improved ...
May 10, 2012 at 05:59 | Source: Reuters
(RTTNews) - Novartis International AG (NVS: News ) said results from the pivotal Phase III GLOW2 study demonstrated that once-daily 50 mcg NVA237 (glycopyrronium bromide) was superior to placebo in improving lung function, symptom relief and quality of ...
May 17, 2012 at 05:29 | Source: RTT News
Switzerland-based pharmaceutical company, Novartis AG (NVS) announced positive results from a phase III study of pasireotide (SOM230) long-acting release (LAR). Results from the trial were presented at the joint 15th International Congress of ...
May 9, 2012 at 16:44 | Source: Yahoo Finance
Law360, New York (May 15, 2012, 4:40 PM ET) -- Swiss drugmaker Novartis International AG on Monday launched separate patent infringement suits against India-based Lupin Pharmaceuticals Inc. and Torrent Pharmaceuticals Ltd. over their bids to manufacture ...
May 15, 2012 at 20:33 | Source: site.law360.com